Want to see GB:APTA full AI Analyst Report?
Aptamer Group Plc (APTA) AI Stock Analysis
Aptamer Group Plc
(LSE:APTA)
The score is held down primarily by persistent operating losses and ongoing cash burn despite improving margins, while a strengthened, low-debt balance sheet provides some stability. Technically, the stock remains in a broader downtrend with weak momentum, and valuation is constrained by negative earnings and no stated dividend yield.
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 9.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 6.85M
- Price to Earnings (P/E)
- -9.5
- Beta (1Y)
- 0.34
- Revenue Growth
- 28.35%
- EPS Growth
- 57.14%
- Country
- UK
- Employees
- 34
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Aptamer Group Plc Business Overview & Revenue Model
Company Description
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...
Aptamer Group Plc Financial Statement Overview
Summary
Balance sheet is a key support with very low leverage (debt-to-equity ~0.03) and higher equity in 2026, but the income statement and cash flow remain weak: sustained deep losses (net margin ~-121% in 2026) and ongoing negative operating cash flow/free cash flow, indicating continued cash burn and reliance on external funding.
Income Statement
32NegativeBalance Sheet
62PositiveCash Flow
38Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.54M | 1.54M | 1.20M | 860.00K | 4.04M | 1.75M |
| Gross Profit | 573.00K | 573.00K | 350.00K | 250.00K | 2.69M | 359.00K |
| EBITDA | -2.60M | -2.60M | -2.28M | -2.81M | -2.20M | -7.36M |
| Net Income | -1.86M | -1.86M | -2.42M | -2.96M | -2.09M | -7.84M |
Balance Sheet | ||||||
| Total Assets | 7.18M | 7.18M | 2.83M | 2.77M | 11.52M | 2.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 4.36M | 1.06M | 870.00K | 6.69M | 234.00K |
| Total Debt | 170.00K | 170.00K | 491.00K | 817.00K | 1.31M | 1.08M |
| Total Liabilities | 1.44M | 1.44M | 1.45M | 1.88M | 3.47M | 2.45M |
| Stockholders Equity | 5.74M | 5.74M | 1.38M | 887.00K | 8.05M | 304.00K |
Cash Flow | ||||||
| Free Cash Flow | -2.30M | -2.30M | -2.01M | -2.41M | -2.79M | -6.09M |
| Operating Cash Flow | -2.13M | -2.13M | -2.00M | -2.28M | -2.38M | -4.06M |
| Investing Cash Flow | -253.00K | -253.00K | -92.00K | -122.00K | -418.00K | -2.03M |
| Financing Cash Flow | 5.68M | 5.68M | 2.28M | 3.04M | 9.12M | -365.00K |
Aptamer Group Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.33, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 18.44 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.
Aptamer Group Plc Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:AVCT43Neutral- GB:APTA43Neutral
GB:OBD40Underperform
GB:FAB35Underperform
GB:AREC33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:BVXP | 89Outperform | GBP 107.11M | 13.96 | 67.81% | 7.41% | -1.10% | 0.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:AVCT | 43Neutral | GBP 279.90M | -6.30 | -1293.07% | ― | ― | ― |
| GB:APTA | 43Neutral | GBP 9.88M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
| GB:OBD | 40Underperform | GBP 13.78M | -0.26 | -451.74% | ― | 33.37% | 86.41% |
| GB:FAB | 35Underperform | GBP 7.51M | -5.81 | -97.87% | ― | 7.38% | 44.13% |
| GB:AREC | 33Underperform | GBP 37.37M | 155.00 | 3.75% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:APTA | Aptamer Group Plc | 0.28 | -0.52 | -64.38% | |
| GB:AVCT | Avacta Group plc | 57.50 | -15.50 | -21.23% | |
| GB:BVXP | Bioventix plc | 2025.00 | -20.67 | -1.01% | |
| GB:OBD | Oxford BioDynamics | 0.10 | -0.20 | -66.00% | |
| GB:FAB | Fusion Antibodies Plc | 5.75 | -7.25 | -55.77% | |
| GB:AREC | Arecor Therapeutics PLC | 77.50 | 5.00 | 6.90% |
Aptamer Group Plc Corporate Events
Aptamer Group lifts revenue and cash as licensing and pharma demand deepen
PositiveAptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the year...
Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results
PositiveAptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The comp...
Aptamer Group Adds Cavendish as Joint Corporate Broker to Bolster Investor Reach
PositiveAptamer Group plc has appointed Cavendish Capital Markets as joint corporate broker alongside Turner Pope Investments, strengthening its capital markets advisory team. The move aims to expand research coverage and deepen institutional engagement as t...
Aptamer Group boosts director stakes and launches major incentive scheme
PositiveAptamer Group has issued 12,936,511 new ordinary shares to remunerate Non-Executive Chairman Adam Hargreaves, via Pathcelerate Limited, and Non-Executive Director Tim Sykes, for services during the year to 30 June 2026. The share-based payments lift...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026